1. FDA. Guidance for industry: In vitro drug interaction studies - cytochrome P45 enzyme- and transporter-mediated drug interactions (January 2020, clinical pharmacology). Website. [Internet]. 2020. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/in-vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions. Accessed 1 June 2023.
2. ICH-M12. ICH Guideline M12 on drug interaction studies - Step 2b [Internet]. 2022. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-m12-drug-interaction-studies-step-2b_en.pdf. Accessed 1 June 2023.
3. EMA. European Medicines Agency (EMA), Committee for Human Medicinal Products (CHMP): guideline on the investigation of drug interactions [Internet]. 2012. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf. Accessed 1 June 2023.
4. PMDA. Ministry of Health, Labour and Welfare: Guideline on drug interaction for drug development and appropriate provision of information [Internet]. 2019. Available from: https://www.pmda.go.jp/files/000228122.pdf. Accessed 1 June 2023.
5. Sane R, Cheung KWK, Kovács P, Farasyn T, Li R, Bui A, et al. Calibrating the in vitro-in vivo correlation for OATP mediated drug-drug interactions with rosuvastatin using static and PBPK models. Drug Metab Dispos. 2020;48:1264–70.